Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2010 (2010), Article ID 789363, 5 pages
http://dx.doi.org/10.1155/2010/789363
Research Article

Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing

1Institute of Pathology and Cytology, HSK Wiesbaden, Academic Hospital of University of Mainz, Ludwig-Erhard-Strasse 100, 65199 Wiesbaden, Germany
2Department of Thoracic Surgery, HSK Wiesbaden, Academic Hospital of University of Mainz, Ludwig-Erhard-Strasse 100, 65199 Wiesbaden, Germany

Received 24 September 2010; Revised 10 November 2010; Accepted 10 November 2010

Academic Editor: Antoni Castells

Copyright © 2010 Rica Zinsky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. Peeters, J. Balfourf, and D. Arnold, “Review article: panitumumab—a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 3, pp. 269–281, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. M. Giusti, K. A. Shastri, M. H. Cohen, P. Keegan, and R. Pazdur, “FDA drug approval summary: panitumumab (Vectibix),” Oncologist, vol. 12, no. 5, pp. 577–583, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. http://www.emea.europa.eu/pdfs/human/opinion/40511307en.pdf.
  5. A. Lièvre, J. B. Bachet, D. Le Corre et al., “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer,” Cancer Research, vol. 66, no. 8, pp. 3992–3995, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. Lièvre, J. B. Bachet, V. Boige et al., “KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 374–379, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. W. De Roock, H. Piessevaux, J. De Schutter et al., “KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab,” Annals of Oncology, vol. 19, no. 3, pp. 508–515, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. F. Di Fiore, F. Blanchard, F. Charbonnier et al., “Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1166–1169, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. L. Bos, “ras oncogenes in human cancer: a review,” Cancer Research, vol. 49, no. 17, pp. 4682–4689, 1989. View at Google Scholar · View at Scopus
  10. S. Schubbert, K. Shannon, and G. Bollag, “Hyperactive Ras in developmental disorders and cancer,” Nature Reviews Cancer, vol. 7, no. 4, pp. 295–308, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. Ogino, T. Kawasaki, M. Brahmandam et al., “Sensitive sequencing method for KRAS mutation detection by pyrosequencing,” Journal of Molecular Diagnostics, vol. 7, no. 3, pp. 413–421, 2005. View at Google Scholar · View at Scopus
  12. http://www.dxsdiagnostics.com/Site/PDF/CMP/TheraScreenKRAS/IFU-KRAS-TheraScreen-ZA.pdf.
  13. W. Weichert, C. Schewe, A. Lehmann et al., “KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology,” Journal of Molecular Diagnostics, vol. 12, no. 1, pp. 35–42, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. D. A. Eberhard, B. E. Johnson, L. C. Amler et al., “Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5900–5909, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. Ogino, J. A. Meyehardt, M. Cantor et al., “Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer,” Clinical Cancer Research, vol. 11, no. 18, pp. 6650–6656, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. Ugorčáková, T. Hlavatý, P. Babál et al., “Assay design and optimization of mutant-enriched PCR based method for detection of K-ras gene mutations in pancreatic carcinoma,” Neoplasma, vol. 53, no. 5, pp. 363–371, 2006. View at Google Scholar
  17. C. Bokemeyer, I. Bondarenko, A. Makhson et al., “Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 663–671, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. G. J. Riely, M. G. Kris, D. Rosenbaum et al., “Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma,” Clinical Cancer Research, vol. 14, no. 18, pp. 5731–5734, 2008. View at Publisher · View at Google Scholar · View at PubMed